China has almost one fifth of all the world’s multi-drug resistant-TB (MDR-TB) cases and the second highest number of TB cases in the world. Over the past 10 years, China has taken some important steps to improve MDR-TB control
This policy brief sets out findings from a study to identify the barriers to case management from the experiences of multi-drug resistant-TB (MDR-TB) patients and providers during 3 periods:
- identification of suspected cases
- MDR-TB diagnosis (sputum culture and drug sensitivity tests)
- MDR-TB treatment.
This research is supported by the Department for International Development’s COMDIS-HSD Programme which is led by the University of Leeds
COMDIS. Improving treatment for multi-drug resistant tuberculosis patients: lessons from Shandong Province, China, COMDIS-HSD Policy Brief (2016), 2p